Samsung Biologics' $1.8 Billion PolyPeptide Acquisition: What Peptide CDMO Consolidation Means for Research Supply Chains

Key takeaways

• Samsung Biologics has launched an all-cash tender offer valued at approximately CHF 1.46 billion ($1.8 billion) to acquire PolyPeptide Group AG, a Swiss CDMO specialising in peptide APIs — the largest biopharma acquisition in South Korean history.
• The formal offer prospectus is due for publication by 31 August 2026, with a minimum acceptance period of twenty trading days thereafter; transaction close is targeted for year-end 2026.
• The deal marks Samsung's first entry into peptide manufacturing and is explicitly driven by surging GLP-1 demand; PolyPeptide reported 41.6% revenue growth in H1 2026, with a material proportion attributable to metabolic therapeutics.
• The acquisition is the latest in a wave of consolidation that includes CordenPharma's acquisition of AmbioPharm and AstraZeneca's $1.2 billion upfront deal with CSPC for long-acting peptide assets.
• For research procurement professionals, concentration of validated GMP solid-phase peptide synthesis (SPPS) capacity among a shrinking number of large operators carries both supply-resilience and pricing implications.

The transaction

Samsung Biologics announced on 20 July 2026 the launch of an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide Group AG, a specialised global CDMO for peptide-based active pharmaceutical ingredients (APIs), listed on the SIX Swiss Exchange under the ticker PPGN. The offer price of CHF 44.31 per share implies an equity value of approximately CHF 1.46 billion, equivalent to roughly $1.8 billion at current exchange rates.

The offer price represents a 40% premium to PolyPeptide's undisturbed share price of CHF 31.65 on 10 April 2026, the last trading day before market rumours of a potential acquisition surfaced, and an approximately 11.6% premium to the 60-day volume-weighted average price.

PolyPeptide's board of directors, acting through its independent and non-conflicted members, has unanimously recommended that shareholders accept the offer, and the company's largest shareholder — Draupnir Holding, which controls approximately 55.65% of outstanding shares — has irrevocably committed to tender its stake. With 55.65% already committed, the 66⅔% acceptance threshold requires only approximately a further 12% of remaining shares to be tendered — a low bar given the unanimous board recommendation.

The formal tender offer prospectus is expected to be published by 31 August 2026 and will remain open for a minimum of twenty trading days on the SIX Swiss Exchange, following a mandatory ten-trading-day cooling-off period under Swiss takeover law. Completion is anticipated towards the end of 2026, subject to the acceptance threshold, applicable regulatory approvals, and other customary conditions. If successful, Samsung Biologics intends to pursue a squeeze-out of remaining minority shares and delist PolyPeptide from the SIX, making it a wholly owned subsidiary.

What Samsung is buying

PolyPeptide Group, established in 1996, specialises in peptide drug candidate development from process design to commercial production. The company has completed more than 1,000 development and manufacturing projects and operates six manufacturing and research facilities across five countries: Sweden, Belgium, France, the United States, and India. It employs approximately 1,500 specialists.

Critically for the GLP-1 context, PolyPeptide's facilities in Braine l'Alleud (Belgium), Torrance (California), and Malmö (Sweden) are engaged in metabolic projects, supporting 37 metabolic development programmes for approximately 25 customers, covering GLP-1s, oral formulations, multiple agonists, and combination therapies. PolyPeptide is also expanding those sites, adding large-scale SPPS capacity at Braine l'Alleud and preparing to ramp up an expansion at its Malmö plant.

PolyPeptide reported preliminary H1 2026 results showing 41.6% revenue growth to EUR 236.6 million, with an EBITDA margin of 20.7%. The company updated its full-year 2026 guidance to 25–30% revenue growth at constant currency, a high-teens EBITDA margin, and capital expenditures of 15–20% of revenue.

Why Samsung is paying a premium

Samsung Biologics, already the world's largest biologics CDMO by bioreactor capacity, has 785,000 litres of capacity across five plants in Incheon, South Korea, with a third campus under development. However, that bioreactor scale is structurally irrelevant to peptide manufacturing. Peptide drugs are chemically assembled using solid-phase peptide synthesis in specialised reactor vessels handling organic solvents, with different analytical instrumentation, different purification equipment, and entirely different regulatory validation requirements. Gaining GMP-validated SPPS suites inspected by multiple regulators cannot be replicated quickly through greenfield construction.

Samsung's CEO John Rim was explicit about the rationale: "This acquisition reinforces our long-term growth strategy by not only broadening our service portfolio with modality expansion into peptides including GLP-1, but by also boosting our geographic reach and proximity further within the US, Europe, and India," he said in a public release. The transaction will enable Samsung Biologics to expand its capabilities to include peptide therapeutics, particularly for treatments targeting obesity and type-2 diabetes, and will also advance the company's goal of expanding into new disease areas.

A broader consolidation wave

The Samsung–PolyPeptide deal does not stand in isolation. The global peptide CDMO market is projected to reach $13.4 billion by 2034, growing at a compound annual rate of approximately 10%, with GLP-1 manufacturing accounting for a growing share; more than 33% of recent capacity additions across the industry have been dedicated specifically to metabolic disorder therapeutics.

Bachem, the Swiss market leader, committed CHF 700 million to new facilities between 2023 and 2026; CordenPharma has invested nearly EUR 1 billion in peptide expansion, including a major facility in the Basel region; Lonza has been expanding solid-phase capacity at its US sites; and Thermo Fisher has built out peptide API capabilities as well.

CordenPharma's acquisition of AmbioPharm, a US- and China-based peptide CDMO, in May 2026 similarly expanded peptide API capacity in response to surging biopharma outsourcing needs. AstraZeneca's $1.2 billion upfront deal with CSPC for long-acting peptide assets reflects the same underlying demand for GLP-1 and related metabolic therapies.

The top five peptide CDMO providers collectively controlled approximately 56% of global peptide manufacturing capacity entering 2026, a share that has been intensifying. Approximately 36% of peptide manufacturers were operating at utilisation rates above 80% through 2025, indicating meaningful tightness in validated capacity ahead of further growth.

Implications for research procurement

The consolidation dynamic presents a dual-edged picture for procurement teams sourcing peptide APIs and research-grade peptide materials.

Capacity additions are net positive for the near term. Samsung Biologics will consider further expanding production capacity as demand for peptide medicines grows, and the combined entity brings a stronger balance sheet to fund the Braine l'Alleud and Malmö expansions already under way. More validated GMP-SPPS capacity, wherever it sits in the supply chain, reduces the structural risk of future API shortages.

Concentration risk warrants monitoring. When a small number of large CDMO operators control the majority of validated GMP-SPPS capacity for drugs millions of patients depend on, a quality failure, a regulatory enforcement action, or operational disruption at any one of them has fewer independent backups to absorb the impact. The current consolidation wave increases total capacity but reduces the number of independent decision-makers managing that capacity; the net effect on supply-chain resilience will take years to assess.

Pricing leverage may shift. M&A premiums for peptide assets averaged 68% to last close across transactions announced in Q1–Q2 2026, according to PeptideStaff investment landscape data, reflecting how scarce validated manufacturing capacity has become. As fewer independent operators compete for contract slots, buyers of peptide API — including research-use suppliers sourcing from the same upstream chain — may find pricing power increasingly concentrated on the sell side.

Transition periods carry operational risk. Change-of-control events at CDMOs historically introduce short-term uncertainty around customer contracts, site personnel, and regulatory filing continuity. Procurement teams with supply agreements routed through PolyPeptide facilities should monitor communications from the combined entity following any formal close, and consider whether their contracts include change-of-control provisions.

The formal prospectus publication, expected by 31 August 2026, will set out the detailed offer conditions and acceptance mechanics under Swiss takeover law. Procurement professionals following this transaction should treat that document as the definitive source for timeline certainty.

This briefing covers publicly available information as of 11 August 2026 and does not constitute financial or legal advice.